You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》大摩上调绿叶制药(02186.HK)目标价至4.1元 评级「与大市同步」
阿思达克 05-26 11:26
摩根士丹利发表报告,将绿叶制药(02186.HK)今明两年的盈利预测分别下调了8%和3%,主要是在销售方面在去年开始出现疲态。

大摩指,绿叶制药主要药品力扑素(Lipusu)纳入国家医保药品目录後有利其前景,但竞争威胁仍然显着,而研发管道缺乏具高增长潜力的产品。该行预计在未来三年盈利温和增长的情况下,2021年至2024年度的复合增长率为8.3%,有关前景改善已被市场消化,目标价由3.8元上调至4.1元,相当於2021年预测市盈率11倍,略低於目前的12倍,评级「与大市同步」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account